Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1994;3(6):403–410. doi: 10.1155/S0962935194000566

Cytokines in Clinical and Experimental Transplantation

Ann C T M Vossen 1, Huub F J Savelkoul 1
PMCID: PMC2365586  PMID: 18475587

Abstract

Allograft rejection is a complex process, which requires interactions between different cell types and a variety of soluble factors, such as cytokines. In this review we discuss the role of cytokines in the induction and effector phases of the rejection process and in the induction and maintenance of allospecific graft tolerance. Furthermore, we discuss the feasibility of clinical graft function monitoring by measuring cytokines and the possibilities for intervention in the cytokine network in order to inhibit graft rejection and eventually obtain graft acceptance.

Full Text

The Full Text of this article is available as a PDF (973.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abramowicz D., Schandene L., Goldman M., Crusiaux A., Vereerstraeten P., De Pauw L., Wybran J., Kinnaert P., Dupont E., Toussaint C. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation. 1989 Apr;47(4):606–608. doi: 10.1097/00007890-198904000-00008. [DOI] [PubMed] [Google Scholar]
  2. Betz M., Fox B. S. Regulation and development of cytochrome c-specific IL-4-producing T cells. J Immunol. 1990 Aug 15;145(4):1046–1052. [PubMed] [Google Scholar]
  3. Beutler B., Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987 Feb 12;316(7):379–385. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
  4. Bierer B. E., Holländer G., Fruman D., Burakoff S. J. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol. 1993 Oct;5(5):763–773. doi: 10.1016/0952-7915(93)90135-f. [DOI] [PubMed] [Google Scholar]
  5. Bolling S. F., Kunkel S. L., Lin H. Prolongation of cardiac allograft survival in rats by anti-TNF and cyclosporine combination therapy. Transplantation. 1992 Feb;53(2):283–286. doi: 10.1097/00007890-199202010-00006. [DOI] [PubMed] [Google Scholar]
  6. Brok H. P., Heidt P. J., van der Meide P. H., Zurcher C., Vossen J. M. Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol. 1993 Dec 1;151(11):6451–6459. [PubMed] [Google Scholar]
  7. Broski A. P., Halloran P. F. Tissue distribution of IL-10 mRNA in normal mice. Evidence that a component of IL-10 expression is T and B cell-independent and increased by irradiation. Transplantation. 1994 Feb 27;57(4):582–592. [PubMed] [Google Scholar]
  8. Brown P. S., Jr, Parenteau G. L., Dirbas F. M., Garsia R. J., Goldman C. K., Bukowski M. A., Junghans R. P., Queen C., Hakimi J., Benjamin W. R. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2663–2667. doi: 10.1073/pnas.88.7.2663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bugeon L., Cuturi M. C., Hallet M. M., Paineau J., Chabannes D., Soulillou J. P. Peripheral tolerance of an allograft in adult rats--characterization by low interleukin-2 and interferon-gamma mRNA levels and by strong accumulation of major histocompatibility complex transcripts in the graft. Transplantation. 1992 Aug;54(2):219–225. doi: 10.1097/00007890-199208000-00006. [DOI] [PubMed] [Google Scholar]
  10. Chatelain R., Varkila K., Coffman R. L. IL-4 induces a Th2 response in Leishmania major-infected mice. J Immunol. 1992 Feb 15;148(4):1182–1187. [PubMed] [Google Scholar]
  11. Cobbold S. P., Martin G., Waldmann H. The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur J Immunol. 1990 Dec;20(12):2747–2755. doi: 10.1002/eji.1830201232. [DOI] [PubMed] [Google Scholar]
  12. Cohen N., Gumbert M., Birnbaum J., Lim V. L., Falco D., Ascher N., Roberts J., Garovoy M. R. An improved method for the detection of soluble interleukin 2 receptors in liver transplant recipients by flow cytometry. Transplantation. 1991 Feb;51(2):417–421. doi: 10.1097/00007890-199102000-00028. [DOI] [PubMed] [Google Scholar]
  13. Collins T., Lapierre L. A., Fiers W., Strominger J. L., Pober J. S. Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci U S A. 1986 Jan;83(2):446–450. doi: 10.1073/pnas.83.2.446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Colvin R. B. Cellular and molecular mechanisms of allograft rejection. Annu Rev Med. 1990;41:361–375. doi: 10.1146/annurev.me.41.020190.002045. [DOI] [PubMed] [Google Scholar]
  15. Colvin R. B., Preffer F. I., Fuller T. C., Brown M. C., Ip S. H., Kung P. C., Cosimi A. B. A critical analysis of serum and urine interleukin-2 receptor assays in renal allograft recipients. Transplantation. 1989 Nov;48(5):800–805. doi: 10.1097/00007890-198911000-00015. [DOI] [PubMed] [Google Scholar]
  16. Dallman M. J., Larsen C. P., Morris P. J. Cytokine gene transcription in vascularised organ grafts: analysis using semiquantitative polymerase chain reaction. J Exp Med. 1991 Aug 1;174(2):493–496. doi: 10.1084/jem.174.2.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Dallman M. J., Montgomery R. A., Larsen C. P., Wanders A., Wells A. F. Cytokine gene expression: analysis using northern blotting, polymerase chain reaction and in situ hybridization. Immunol Rev. 1991 Feb;119:163–179. doi: 10.1111/j.1600-065x.1991.tb00583.x. [DOI] [PubMed] [Google Scholar]
  18. Dallman M. J., Roake J., Hughes D., Toogood G., Morris P. J. Sequential analysis of IL-2 gene transcription in renal transplants. Transplantation. 1992 Mar;53(3):683–685. doi: 10.1097/00007890-199203000-00038. [DOI] [PubMed] [Google Scholar]
  19. Dallman M. J., Shiho O., Page T. H., Wood K. J., Morris P. J. Peripheral tolerance to alloantigen results from altered regulation of the interleukin 2 pathway. J Exp Med. 1991 Jan 1;173(1):79–87. doi: 10.1084/jem.173.1.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Debets J. M., Leunissen K. M., van Hooff H. J., van der Linden C. J., Buurman W. A. Evidence of involvement of tumor necrosis factor in adverse reactions during treatment of kidney allograft rejection with antithymocyte globulin. Transplantation. 1989 Mar;47(3):487–492. doi: 10.1097/00007890-198903000-00018. [DOI] [PubMed] [Google Scholar]
  21. Diamantstein T., Mouzaki A., Osawa H., Volk H. D., Hahn H. J., Kirkman R. L., Strom T. B., Tilney N. L., Kupiec-Weglinski J. W. Inhibition of allograft rejection and organ-specific autoimmune disease by anti-interleukin-2 receptor (IL-2R)-targeted immunotherapy. The action of anti-IL-2R monoclonal antibodies and synergistic effect of cyclosporin A. Dev Biol Stand. 1988;69:177–184. [PubMed] [Google Scholar]
  22. Didlake R. H., Kim E. K., Sheehan K., Schreiber R. D., Kahan B. D. Effect of combined anti-gamma interferon antibody and cyclosporine therapy on cardiac allograft survival in the rat. Transplantation. 1988 Jan;45(1):222–223. [PubMed] [Google Scholar]
  23. Durum S. K., Schmidt J. A., Oppenheim J. J. Interleukin 1: an immunological perspective. Annu Rev Immunol. 1985;3:263–287. doi: 10.1146/annurev.iy.03.040185.001403. [DOI] [PubMed] [Google Scholar]
  24. Fanslow W. C., Clifford K. N., Park L. S., Rubin A. S., Voice R. F., Beckmann M. P., Widmer M. B. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J Immunol. 1991 Jul 15;147(2):535–540. [PubMed] [Google Scholar]
  25. Fanslow W. C., Sims J. E., Sassenfeld H., Morrissey P. J., Gillis S., Dower S. K., Widmer M. B. Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science. 1990 May 11;248(4956):739–742. doi: 10.1126/science.2139736. [DOI] [PubMed] [Google Scholar]
  26. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J. 1991 Aug;5(11):2567–2574. doi: 10.1096/fasebj.5.11.1868981. [DOI] [PubMed] [Google Scholar]
  27. Ferrara J. L., Marion A., McIntyre J. F., Murphy G. F., Burakoff S. J. Amelioration of acute graft vs host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody. J Immunol. 1986 Sep 15;137(6):1874–1877. [PubMed] [Google Scholar]
  28. Field E. H., Rouse T. M., Fleming A. L., Jamali I., Cowdery J. S. Altered IFN-gamma and IL-4 pattern lymphokine secretion in mice partially depleted of CD4 T cells by anti-CD4 monoclonal antibody. J Immunol. 1992 Aug 15;149(4):1131–1137. [PubMed] [Google Scholar]
  29. Fiorentino D. F., Bond M. W., Mosmann T. R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989 Dec 1;170(6):2081–2095. doi: 10.1084/jem.170.6.2081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Gajewski T. F., Fitch F. W. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol. 1988 Jun 15;140(12):4245–4252. [PubMed] [Google Scholar]
  31. Gajewski T. F., Joyce J., Fitch F. W. Antiproliferative effect of IFN-gamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-gamma. J Immunol. 1989 Jul 1;143(1):15–22. [PubMed] [Google Scholar]
  32. Gascoigne A. D., Shenton B. K., White M. D., Colquhoun I. W., Dark J. H., Corris P. A. The value of plasma-soluble interleukin 2 receptor monitoring in lung transplantation. Transplantation. 1993 Oct;56(4):1029–1031. [PubMed] [Google Scholar]
  33. Gilbert K. M., Weigle W. O. B cell presentation of a tolerogenic signal to Th clones. Cell Immunol. 1992 Jan;139(1):58–71. doi: 10.1016/0008-8749(92)90099-b. [DOI] [PubMed] [Google Scholar]
  34. Haak-Frendscho M., Marsters S. A., Mordenti J., Brady S., Gillett N. A., Chen S. A., Ashkenazi A. Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody. J Immunol. 1994 Feb 1;152(3):1347–1353. [PubMed] [Google Scholar]
  35. Hiesse C., Kriaa F., Alard P., Lantz O., Noury J., Bensadoun H., Benoit G., Charpentier B., Fries D., Bazin H. Prophylactic use of the IL-2 receptor-specific monoclonal antibody LO-Tact-1 with cyclosporin A and steroids in renal transplantation. Transpl Int. 1992;5 (Suppl 1):S444–S447. doi: 10.1007/978-3-642-77423-2_129. [DOI] [PubMed] [Google Scholar]
  36. Hsieh C. S., Heimberger A. B., Gold J. S., O'Garra A., Murphy K. M. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6065–6069. doi: 10.1073/pnas.89.13.6065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Humbert M., Emilie D., Cerrina J., Simonneau G., Rain B., Fattal S., Le Roy Ladurie F., Dartevelle P., Duroux P., Galanaud P. Soluble interleukin 2 receptor and neopterin serum levels after lung/heart-lung transplantations--absence of predictive value for late allograft rejection. Transplantation. 1991 Dec;52(6):1092–1094. [PubMed] [Google Scholar]
  38. Häyry P. Mechanisms of rejection. Curr Opin Immunol. 1989 Aug;1(6):1230–1235. doi: 10.1016/0952-7915(89)90021-6. [DOI] [PubMed] [Google Scholar]
  39. Imagawa D. K., Millis J. M., Olthoff K. M., Derus L. J., Chia D., Sugich L. R., Ozawa M., Dempsey R. A., Iwaki Y., Levy P. J. The role of tumor necrosis factor in allograft rejection. I. Evidence that elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation. Transplantation. 1990 Aug;50(2):219–225. doi: 10.1097/00007890-199008000-00009. [DOI] [PubMed] [Google Scholar]
  40. Imagawa D. K., Millis J. M., Olthoff K. M., Seu P., Dempsey R. A., Hart J., Terasaki P. I., Wasef E. M., Busuttil R. W. The role of tumor necrosis factor in allograft rejection. II. Evidence that antibody therapy against tumor necrosis factor-alpha and lymphotoxin enhances cardiac allograft survival in rats. Transplantation. 1990 Aug;50(2):189–193. doi: 10.1097/00007890-199008000-00003. [DOI] [PubMed] [Google Scholar]
  41. Imagawa D. K., Millis J. M., Seu P., Olthoff K. M., Hart J., Wasef E., Dempsey R. A., Stephens S., Busuttil R. W. The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. Transplantation. 1991 Jan;51(1):57–62. doi: 10.1097/00007890-199101000-00008. [DOI] [PubMed] [Google Scholar]
  42. Jenkins M. K., Johnson J. G. Molecules involved in T-cell costimulation. Curr Opin Immunol. 1993 Jun;5(3):361–367. doi: 10.1016/0952-7915(93)90054-v. [DOI] [PubMed] [Google Scholar]
  43. Jenkins M. K., Mueller D., Schwartz R. H., Carding S., Bottomley K., Stadecker M. J., Urdahl K. B., Norton S. D. Induction and maintenance of anergy in mature T cells. Adv Exp Med Biol. 1991;292:167–176. doi: 10.1007/978-1-4684-5943-2_19. [DOI] [PubMed] [Google Scholar]
  44. Jenkins M. K., Pardoll D. M., Mizuguchi J., Chused T. M., Schwartz R. H. Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5409–5413. doi: 10.1073/pnas.84.15.5409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Kaye J., Gillis S., Mizel S. B., Shevach E. M., Malek T. R., Dinarello C. A., Lachman L. B., Janeway C. A., Jr Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol. 1984 Sep;133(3):1339–1345. [PubMed] [Google Scholar]
  46. Kirkman R. L., Bacha P., Barrett L. V., Forte S., Murphy J. R., Strom T. B. Prolongation of cardiac allograft survival in murine recipients treated with a diphtheria toxin-related interleukin-2 fusion protein. Transplantation. 1989 Feb;47(2):327–330. doi: 10.1097/00007890-198902000-00028. [DOI] [PubMed] [Google Scholar]
  47. Kirkman R. L., Barrett L. V., Gaulton G. N., Kelley V. E., Koltun W. A., Schoen F. J., Ythier A., Strom T. B. The effect of anti-interleukin-2 receptor monoclonal antibody on allograft rejection. Transplantation. 1985 Dec;40(6):719–722. doi: 10.1097/00007890-198512000-00029. [DOI] [PubMed] [Google Scholar]
  48. Kirkman R. L., Shapiro M. E., Carpenter C. B., McKay D. B., Milford E. L., Ramos E. L., Tilney N. L., Waldmann T. A., Zimmerman C. E., Strom T. B. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation. 1991 Jan;51(1):107–113. doi: 10.1097/00007890-199101000-00016. [DOI] [PubMed] [Google Scholar]
  49. Kita Y., Iwaki Y., Demetris A. J., Starzl T. E. Evaluation of sequential serum interleukin-6 levels in liver allograft recipients. Transplantation. 1994 Apr 15;57(7):1037–1041. doi: 10.1097/00007890-199404150-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Kupiec-Weglinski J. W., Tilney N. L., Stunkel K. G., Grutzmann R., van der Meide P. H., Di Stefano R., Diamantstein T. Agonistic and antagonistic interactions of anti-interleukin 2 receptor monoclonal antibodies in rat recipients of cardiac allografts. Transplantation. 1989 Jan;47(1):11–16. doi: 10.1097/00007890-198901000-00004. [DOI] [PubMed] [Google Scholar]
  51. Kühn R., Rajewsky K., Müller W. Generation and analysis of interleukin-4 deficient mice. Science. 1991 Nov 1;254(5032):707–710. doi: 10.1126/science.1948049. [DOI] [PubMed] [Google Scholar]
  52. Le Gros G., Ben-Sasson S. Z., Seder R., Finkelman F. D., Paul W. E. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med. 1990 Sep 1;172(3):921–929. doi: 10.1084/jem.172.3.921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Lenschow D. J., Bluestone J. A. T cell co-stimulation and in vivo tolerance. Curr Opin Immunol. 1993 Oct;5(5):747–752. doi: 10.1016/0952-7915(93)90132-c. [DOI] [PubMed] [Google Scholar]
  54. Lenschow D. J., Zeng Y., Thistlethwaite J. R., Montag A., Brady W., Gibson M. G., Linsley P. S., Bluestone J. A. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science. 1992 Aug 7;257(5071):789–792. doi: 10.1126/science.1323143. [DOI] [PubMed] [Google Scholar]
  55. Liu Y., Linsley P. S. Costimulation of T-cell growth. Curr Opin Immunol. 1992 Jun;4(3):265–270. doi: 10.1016/0952-7915(92)90075-p. [DOI] [PubMed] [Google Scholar]
  56. Lorberboum-Galski H., Barrett L. V., Kirkman R. L., Ogata M., Willingham M. C., FitzGerald D. J., Pastan I. Cardiac allograft survival in mice treated with IL-2-PE40. Proc Natl Acad Sci U S A. 1989 Feb;86(3):1008–1012. doi: 10.1073/pnas.86.3.1008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Maeda H., Takata M., Takahashi S., Ogoshi S., Fujimoto S. Adoptive transfer of a Th2-like cell line prolongs MHC class II antigen disparate skin allograft survival in the mouse. Int Immunol. 1994 Jun;6(6):855–862. doi: 10.1093/intimm/6.6.855. [DOI] [PubMed] [Google Scholar]
  58. Maessen J. G., Buurman W. A., Kootstra G. Direct cytotoxic effect of cytokines in kidney parenchyma: a possible mechanism of allograft destruction. Transplant Proc. 1989 Feb;21(1 Pt 1):309–310. [PubMed] [Google Scholar]
  59. Martinez O. M., Krams S. M., Sterneck M., Villanueva J. C., Falco D. A., Ferrell L. D., Lake J., Roberts J. P., Ascher N. L. Intragraft cytokine profile during human liver allograft rejection. Transplantation. 1992 Feb;53(2):449–456. doi: 10.1097/00007890-199202010-00035. [DOI] [PubMed] [Google Scholar]
  60. Maury C. P., Teppo A. M. Raised serum levels of cachectin/tumor necrosis factor alpha in renal allograft rejection. J Exp Med. 1987 Oct 1;166(4):1132–1137. doi: 10.1084/jem.166.4.1132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. McLaughlin P. J., Aikawa A., Davies H. M., Ward R. G., Bakran A., Sells R. A., Johnson P. M. Evaluation of sequential plasma and urinary tumor necrosis factor alpha levels in renal allograft recipients. Transplantation. 1991 Jun;51(6):1225–1229. doi: 10.1097/00007890-199106000-00015. [DOI] [PubMed] [Google Scholar]
  62. Mohler K. M., Torrance D. S., Smith C. A., Goodwin R. G., Stremler K. E., Fung V. P., Madani H., Widmer M. B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993 Aug 1;151(3):1548–1561. [PubMed] [Google Scholar]
  63. Morel D., Normand E., Lemoine C., Merlio J. P., Velours J., Astier T., Bonnet F., Aparicio M., Potaux L., Bloch B. Tumor necrosis factor alpha in human kidney transplant rejection--analysis by in situ hybridization. Transplantation. 1993 Apr;55(4):773–777. doi: 10.1097/00007890-199304000-00017. [DOI] [PubMed] [Google Scholar]
  64. Morgan C., Pelletier R., Hernandez C., Teske D., Huang E., Ohye R., Ferguson R., Orosz C. Cytokine mRNA expression during development of acute rejection in murine cardiac allografts. Transplant Proc. 1993 Feb;25(1 Pt 1):114–116. [PubMed] [Google Scholar]
  65. Mosmann T. R., Coffman R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–173. doi: 10.1146/annurev.iy.07.040189.001045. [DOI] [PubMed] [Google Scholar]
  66. Nast C. C., Zuo X. J., Prehn J., Danovitch G. M., Wilkinson A., Jordan S. C. Gamma-interferon gene expression in human renal allograft fine-needle aspirates. Transplantation. 1994 Feb 27;57(4):498–502. [PubMed] [Google Scholar]
  67. Nguyen D. T., Eskandai M. K., DeForge L. E., Raiford C. L., Strieter R. M., Kunkel S. L., Remick D. G. Cyclosporin a modulation of tumor necrosis factor gene expression and effects in vitro and in vivo. J Immunol. 1990 May 15;144(10):3822–3828. [PubMed] [Google Scholar]
  68. O'Garra A. Interleukins and the immune system 1. Lancet. 1989 Apr 29;1(8644):943–947. [PubMed] [Google Scholar]
  69. O'Garra A. Interleukins and the immune system 2. Lancet. 1989 May 6;1(8645):1003–1005. doi: 10.1016/s0140-6736(89)92640-8. [DOI] [PubMed] [Google Scholar]
  70. Paineau J., Priestley C., Fabre J., Chevalier S., van der Meide P., Jacques Y., Soulillou J. P. Effects of gamma interferon and interleukin-2, and of gamma-interferon antibodies, on the rat immune response against allografts. Transplant Proc. 1989 Feb;21(1 Pt 1):999–1001. [PubMed] [Google Scholar]
  71. Papp I., Wieder K. J., Sablinski T., O'Connell P. J., Milford E. L., Strom T. B., Kupiec-Weglinski J. W. Evidence for functional heterogeneity of rat CD4+ T cells in vivo. Differential expression of IL-2 and IL-4 mRNA in recipients of cardiac allografts. J Immunol. 1992 Mar 1;148(5):1308–1314. [PubMed] [Google Scholar]
  72. Pearson T. C., Darby C. R., Bushell A. R., West L. J., Morris P. J., Wood K. J. The assessment of transplantation tolerance induced by anti-CD4 monoclonal antibody in the murine model. Transplantation. 1993 Feb;55(2):361–367. doi: 10.1097/00007890-199302000-00025. [DOI] [PubMed] [Google Scholar]
  73. Perkins J. D., Nelson D. L., Rakela J., Grambsch P. M., Krom R. A. Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. Transplantation. 1989 Jan;47(1):77–81. doi: 10.1097/00007890-198901000-00018. [DOI] [PubMed] [Google Scholar]
  74. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today. 1991 Aug;12(8):256–257. doi: 10.1016/0167-5699(91)90120-I. [DOI] [PubMed] [Google Scholar]
  75. Rosenberg A. S., Finbloom D. S., Maniero T. G., Van der Meide P. H., Singer A. Specific prolongation of MHC class II disparate skin allografts by in vivo administration of anti-IFN-gamma monoclonal antibody. J Immunol. 1990 Jun 15;144(12):4648–4650. [PubMed] [Google Scholar]
  76. Rubin L. A., Nelson D. L. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990 Oct 15;113(8):619–627. doi: 10.7326/0003-4819-113-8-619. [DOI] [PubMed] [Google Scholar]
  77. Rush D. N., Henry S. F., Jeffery J. R., Schroeder T. J., Gough J. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation. 1994 Jan;57(2):208–211. doi: 10.1097/00007890-199401001-00009. [DOI] [PubMed] [Google Scholar]
  78. Sadick M. D., Heinzel F. P., Holaday B. J., Pu R. T., Dawkins R. S., Locksley R. M. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J Exp Med. 1990 Jan 1;171(1):115–127. doi: 10.1084/jem.171.1.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Sakagami K., Ohsaki T., Ohnishi T., Saito S., Matsuoka J., Orita K. The effect of anti-interleukin 2 monoclonal antibody treatment on the survival of rat cardiac allograft. J Surg Res. 1989 Mar;46(3):262–266. doi: 10.1016/0022-4804(89)90068-1. [DOI] [PubMed] [Google Scholar]
  80. Schorle H., Holtschke T., Hünig T., Schimpl A., Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature. 1991 Aug 15;352(6336):621–624. doi: 10.1038/352621a0. [DOI] [PubMed] [Google Scholar]
  81. Schwartz R. H. A cell culture model for T lymphocyte clonal anergy. Science. 1990 Jun 15;248(4961):1349–1356. doi: 10.1126/science.2113314. [DOI] [PubMed] [Google Scholar]
  82. Shalaby M. R., Aggarwal B. B., Rinderknecht E., Svedersky L. P., Finkle B. S., Palladino M. A., Jr Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol. 1985 Sep;135(3):2069–2073. [PubMed] [Google Scholar]
  83. Siegling A., Lehmann M., Riedel H., Platzer C., Brock J., Emmrich F., Volk H. D. A nondepleting anti-rat CD4 monoclonal antibody that suppresses T helper 1-like but not T helper 2-like intragraft lymphokine secretion induces long-term survival of renal allografts. Transplantation. 1994 Feb;57(3):464–467. doi: 10.1097/00007890-199402150-00028. [DOI] [PubMed] [Google Scholar]
  84. Silva J. S., Morrissey P. J., Grabstein K. H., Mohler K. M., Anderson D., Reed S. G. Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med. 1992 Jan 1;175(1):169–174. doi: 10.1084/jem.175.1.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Simpson M. A., Madras P. N., Cornaby A. J., Etienne T., Dempsey R. A., Clowes G. H., Monaco A. P. Sequential determinations of urinary cytology and plasma and urinary lymphokines in the management of renal allograft recipients. Transplantation. 1989 Feb;47(2):218–223. doi: 10.1097/00007890-198902000-00004. [DOI] [PubMed] [Google Scholar]
  86. Soulillou J. P., Cantarovich D., Le Mauff B., Giral M., Robillard N., Hourmant M., Hirn M., Jacques Y. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med. 1990 Apr 26;322(17):1175–1182. doi: 10.1056/NEJM199004263221702. [DOI] [PubMed] [Google Scholar]
  87. Strom T. B. The cellular and molecular basis of allograft rejection: what do we know? Transplant Proc. 1988 Apr;20(2):143–146. [PubMed] [Google Scholar]
  88. Swain S. L., Huston G., Tonkonogy S., Weinberg A. Transforming growth factor-beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J Immunol. 1991 Nov 1;147(9):2991–3000. [PubMed] [Google Scholar]
  89. Swain S. L., Weinberg A. D., English M., Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol. 1990 Dec 1;145(11):3796–3806. [PubMed] [Google Scholar]
  90. Takeuchi T., Lowry R. P., Konieczny B. Heart allografts in murine systems. The differential activation of Th2-like effector cells in peripheral tolerance. Transplantation. 1992 Jun;53(6):1281–1294. [PubMed] [Google Scholar]
  91. Tellides G., Dallman M. J., Morris P. J. Mechanism of action of interleukin-2 receptor (IL-2R) monoclonal antibody (MAb) therapy: target cell depletion or inhibition of function? Transplant Proc. 1989 Feb;21(1 Pt 1):997–998. [PubMed] [Google Scholar]
  92. Tono T., Monden M., Yoshizaki K., Valdivia L. A., Nakano Y., Gotoh M., Ohzato H., Doki Y., Ogata A., Kishimoto T. Biliary interleukin 6 levels as indicators of hepatic allograft rejection in rats. Transplantation. 1992 Jun;53(6):1195–1201. doi: 10.1097/00007890-199206000-00005. [DOI] [PubMed] [Google Scholar]
  93. Tracey K. J., Vlassara H., Cerami A. Cachectin/tumour necrosis factor. Lancet. 1989 May 20;1(8647):1122–1126. doi: 10.1016/s0140-6736(89)92394-5. [DOI] [PubMed] [Google Scholar]
  94. Turka L. A., Linsley P. S., Lin H., Brady W., Leiden J. M., Wei R. Q., Gibson M. L., Zheng X. G., Myrdal S., Gordon D. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):11102–11105. doi: 10.1073/pnas.89.22.11102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Van Oers M. H., Van der Heyden A. A., Aarden L. A. Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clin Exp Immunol. 1988 Feb;71(2):314–319. [PMC free article] [PubMed] [Google Scholar]
  96. Vandenbroecke C., Caillat-Zucman S., Legendre C., Noel L. H., Kreis H., Woodrow D., Bach J. F., Tovey M. G. Differential in situ expression of cytokines in renal allograft rejection. Transplantation. 1991 Mar;51(3):602–609. doi: 10.1097/00007890-199103000-00012. [DOI] [PubMed] [Google Scholar]
  97. Waldmann T. A. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science. 1986 May 9;232(4751):727–732. doi: 10.1126/science.3008337. [DOI] [PubMed] [Google Scholar]
  98. Wecker H., Auchincloss H., Jr Cellular mechanisms of rejection. Curr Opin Immunol. 1992 Oct;4(5):561–566. doi: 10.1016/0952-7915(92)90026-b. [DOI] [PubMed] [Google Scholar]
  99. Williams M. E., Shea C. M., Lichtman A. H., Abbas A. K. Antigen receptor-mediated anergy in resting T lymphocytes and T cell clones. Correlation with lymphokine secretion patterns. J Immunol. 1992 Sep 15;149(6):1921–1926. [PubMed] [Google Scholar]
  100. Wood K. J., Evins J., Morris P. J. Suppression of renal allograft rejection in the rat by class I antigens on purified erythrocytes. Transplantation. 1985 Jan;39(1):56–62. doi: 10.1097/00007890-198501000-00006. [DOI] [PubMed] [Google Scholar]
  101. Wood K. J., Hopley A., Dallman M. J., Morris P. J. Lack of correlation between the induction of donor class I and class II major histocompatibility complex antigens and graft rejection. Transplantation. 1988 Apr;45(4):759–767. doi: 10.1097/00007890-198804000-00019. [DOI] [PubMed] [Google Scholar]
  102. Yoshimura N., Kahan B. D., Oka T. The in vivo effect of cyclosporine on interleukin-6 gene expression in renal transplant recipients. Transplant Proc. 1991 Feb;23(1 Pt 2):958–960. [PubMed] [Google Scholar]
  103. Yoshimura N., Oka T., Kahan B. D. Sequential determinations of serum interleukin 6 levels as an immunodiagnostic tool to differentiate rejection from nephrotoxicity in renal allograft recipients. Transplantation. 1991 Jan;51(1):172–176. doi: 10.1097/00007890-199101000-00026. [DOI] [PubMed] [Google Scholar]
  104. Young-Fadok T. M., Simpson M. A., Madras P. N., Dempsey R. A., O'Connor K., Monaco A. P. Predictive value of pretransplant IL-2 levels in kidney transplantation. Transplant Proc. 1991 Feb;23(1 Pt 2):1295–1296. [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES